Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISANOX: FOLFIRINOX Induction in Rectal Cancer
NCT05868317Phase 2Unknown
- Sponsor
- Salah Azaïz Cancer Institute
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, oxaliplatin and irinotecan in rectal cancer, sponsored by Salah Azaïz Cancer Institute. Primary endpoint: Pathologic Complete Response. Status: unknown.
02
Drugs
fluorouraciloxaliplatinirinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05868317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05868317.